Corient Private Wealth
KRYS icon

Corient Private Wealth’s Krystal Biotech KRYS Stock Holding History

Corient Private Wealth’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
30,558
+27,035
+767% +$8.08M 0.02% 598
2026
Q1 		$818K Sell
3,523
-34,823
-91% -$9.27M ﹤0.01% 1762
2025
Q4 		$9.5M Sell
38,346
-784
-2% -$165K 0.01% 576
2025
Q3 		$6.92M Sell
39,130
-1,408
-3% -$211K 0.01% 610
2025
Q2 		$5.57M Sell
40,538
-1,589
-4% -$233K 0.01% 672
2025
Q1 		$7.6M Sell
42,127
-882
-2% -$148K 0.01% 576
2024
Q4 		$6.74M Sell
43,009
-4,678
-10% -$830K 0.01% 617
2024
Q3 		$8.68M Sell
47,687
-17,313
-27% -$3.34M 0.01% 600
2024
Q2 		$11.9M Buy
65,000
+29,028
+81% +$4.87M 0.02% 486
2024
Q1 		$6.4M Buy
+35,972
New +$5M 0.01% 642

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corient Private Wealth's KRYS Position: Q2 2026 in Review

Corient Private Wealth increased its Krystal Biotech (KRYS) stake by 767% in Q2 2026, buying an estimated $8.08M and bringing the position to 30,558 shares worth $11.4M. The position accounts for 0.02% of the portfolio, ranked #598.

Corient Private Wealth first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.9M in Q2 2024. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Corient Private Wealth held 30,558 shares of Krystal Biotech worth $11.4M as of Q2 2026.
  • Corient Private Wealth bought 27,035 Krystal Biotech shares in Q2 2026, an estimated $8.08M.
  • Krystal Biotech made up 0.02% of Corient Private Wealth's portfolio in Q2 2026, its #598 holding.
  • Corient Private Wealth first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • Corient Private Wealth's Krystal Biotech position peaked at $11.9M in Q2 2024.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.